Second primary or metastases? Comparing DNA of tumours using loss of heterogeneity (LOH) and p53 mutations is of importance in clinical decision making

Authors :: Pieter E. Zondervan
J.A Bekkers
J.R.M van der Sijp
Winand N.M. Dinjens
J. Van Meerbeeck
Hein F.B.M. Sleddens
Source :: Lung Cancer. 29:246
Publication Year :: 2000
Publisher :: Elsevier BV, 2000.

Subjects :: Pulmonary and Respiratory Medicine
Cancer Research
chemistry.chemical_compound
Oncology
Clinical decision making
chemistry
business.industry
Medicine
Second primary cancer
business
Bioinformatics
DNA

Tools